Treatment patterns and outcomes in patients with chronic urticaria during pregnancy: Results of PREG-CU, a UCARE study.

Autor: Kocatürk E; Department of Dermatology, Urticaria Center of Reference, and Excellence (UCARE), Koç University School of Medicine, Istanbul, Turkey.; Institute of Allergology, Urticaria Center of Reference and Excellence (UCARE), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Berlin, Germany., Al-Ahmad M; Microbiology Department, Faculty of Medicine, Urticaria Center of Reference, and Excellence (UCARE), Kuwait University, Safat, Kuwait., Krause K; Institute of Allergology, Urticaria Center of Reference and Excellence (UCARE), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Berlin, Germany., Gimenez-Arnau AM; Department of Dermatology, Urticaria Center of Reference, and Excellence (UCARE), Hospital del Mar, IMIM, Universitat Pompeu Fabra, Barcelona, Spain., Thomsen SF; Department of Dermatology, Urticaria Center of Reference, and Excellence (UCARE), Bispebjerg Hospital, Copenhagen, Denmark., Conlon N; Department of Immunology, Urticaria Center of Reference and Excellence (UCARE), St. James's Hospital, Dublin and Trinity College, Dublin, Ireland., Marsland A; Department of Dermatology, Urticaria Center of Reference, and Excellence (UCARE), The Urticaria Clinic, Salford Royal Foundation Trust, University of Manchester, Manchester, UK., Savk E; Aydın Adnan Menderes University, Aydın, Turkey., Criado RF; Department of Dermatology, Urticaria Center of Reference and Excellence (UCARE), Faculdade de Medicina do ABC (FMABC), Santo André, Brazil., Danilycheva I; NRC Institute of Immunology, FMBA of Russia, Moscow, Russia., Fomina D; First Moscow State Medical University, Moscow, Russia.; Urticaria Center of Reference and Excellence (UCARE), Moscow Center of Allergy and Immunology, Clinical Hospital 52, Ministry of Moscow Healthcare, Moscow, Russia., Godse K; Dr. D.Y. Patil Medical College & Hospital, Mumbai, India., Khoshkhui M; Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Gelincik A; Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey., Degirmentepe EN; Okmeydani Training and Research Hospital, Istanbul, Turkey., Demir S; Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey., Ensina LF; Federal University of São Paulo, Sao Paulo, Brazil., Kasperska-Zajac A; European Center for Diagnosis and Treatment of Urticaria (GA2LEN UCARE Network), Medical University of Silesia in Katowice, Katowice, Poland., Rudenko M; The London Allergy & Immunology Centre, London, UK., Valle S; Federal University of Rio de Janeiro, Rio De Janeiro, Brazil., Medina I; The Centro Médico Vitae, Buenos Aires, Argentina., Bauer A; Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany., Zhao Z; Department of Dermatology and Venerology, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses and National Clinical Research Center for Skin and Immune Diseases, Peking University First Hospital, Beijing, China., Staubach P; Department of Dermatology, University Medical Center, Mainz, Germany., Bouillet L; CHU de Grenoble Alpes, Grenoble, France., Küçük ÖS; Department of Dermatology and Venerology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey., Baygül A; Department of Biostatistics, Koç University School of Medicine, Istanbul, Turkey., Maurer M; Institute of Allergology, Urticaria Center of Reference and Excellence (UCARE), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Berlin, Germany.
Jazyk: angličtina
Zdroj: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2023 Feb; Vol. 37 (2), pp. 356-364. Date of Electronic Publication: 2022 Sep 17.
DOI: 10.1111/jdv.18574
Abstrakt: Background: Although chronic urticaria (CU) is a common and primarily affects females, there is little data on how pregnancy interacts with the disease.
Objective: To analyse the treatment use by CU patients before, during and after pregnancy as well as outcomes of pregnancy.
Methods: PREG-CU is an international, multicentre study of the Urticaria Centers of Reference and Excellence network. Data were collected via a 47-item-questionnaire completed by CU patients who became pregnant during their disease course.
Results: Questionnaires from 288 CU patients from 13 countries were analysed. During pregnancy, most patients (60%) used urticaria medication including standard-dose second generation H1-antihistamines (35.1%), first generation H1-antihistamines (7.6%), high-dose second-generation H1-antihistamines (5.6%) and omalizumab (5.6%). The preterm birth rate was 10.2%; rates were similar between patients who did and did not receive treatment during pregnancy (11.6% vs. 8.7%, respectively). Emergency referrals for CU and twin birth were risk factors for preterm birth. The caesarean delivery rate was 51.3%. More than 90% of new-borns were healthy at birth. There was no link between any patient or disease characteristics or treatments and medical problems at birth.
Conclusion: Most CU patients used treatment during pregnancy especially second-generation antihistamines which seem to be safe during pregnancy regardless of the trimester. The rates of preterm births and medical problems of new-borns in CU patients were similar to population norms and not linked to treatment used during pregnancy. Emergency referrals for CU increased the risk of preterm birth and emphasize the importance of sufficient treatment to keep urticaria under control during pregnancy.
(© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)
Databáze: MEDLINE
Externí odkaz: